Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin

• Published in: Life sciences (1973) 2020-07, Vol.253, p.117725-9, Article 117725
• Main Authors: Saad, Zeinab A., Khodeer, Dina M., Zaitone, Sawsan A., Ahmed, Amal A.M., Moustafa, Yasser M.
• Format: Article
• Language: English
• Subjects: Animal models; Blood; Blood glucose; Body weight; Body weight gain; Degeneration; Diet; Drug therapy; Enzymes; Exenatide; Fatty liver; High fat diet; Homeostasis; Hyperglycemia; Hyperinsulinemia; Hypertriglyceridemia; IL-6; Inflammation; Insulin; Insulin resistance; Lipids; Liver; Liver diseases; Metformin; NAFLD; NF-κB protein; NFκB; Peroxides; Rodents; TLR4 protein; Toll-like receptors; Toll-R4; Tumor necrosis factor-α
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2020.117725

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. This study aimed to evaluate the role of exenatide compared with metformin in halting the progression of fatty liver stimulated by a high-fat diet (HiFD) in rats. Thirty male Wistar rats were allocated into 6 groups, 5 rats per each group. Group I: maintained on normal diet (normal group) for fourteen weeks. The other five groups were kept on HiFD throughout the experiment, HiFD was administered beside pharmacological treatments/or vehicle. Group II: (NAFLD control group), group III: received metformin (60 mg/kg/day, P.O.), group IV-VI: received exenatide (10, 20, and 40 μg/kg/day, S.C.) respectively for 7 weeks. At the end of the therapeutic period, fasting blood glucose was determined, and body weight was registered. Rats were sacrificed, and blood samples were taken to measure serum insulin, lipids, and liver enzymes. The liver index and homeostasis model of insulin resistance (HOMA-IR) index were calculated. Further, livers were dissected for histopathological examination and Western blot analysis. NAFLD control group showed hyperglycemia, hyperinsulinemia, increased liver enzymes, hypertriglyceridemia, elevated hepatic lipid peroxides, and inflammatory mediators (interlukin 6, nuclear factor-κB, tumor necrosis factor-α and Toll-like receptor4) in addition to hepatic fatty degeneration. In a dose-dependent manner, exenatide significantly improved most of the above mentioned markers in comparsion with NAFLD at P≤0.05. The current results suggest that exenatide is equivalent to metformin in controlling insulin resistance, body weight gain, improving liver function, suppressing inflammation, and attenuating NAFLD progression in male rats.